<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03717545</url>
  </required_header>
  <id_info>
    <org_study_id>2nd tx for GF</org_study_id>
    <nct_id>NCT03717545</nct_id>
  </id_info>
  <brief_title>Second Transplantation for Graft Failure</brief_title>
  <official_title>Second Transplantation for Graft Failure After First Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Graft failure is a lethal complication after allogeneic stem cell transplantation, which
      often need a salvage transplantation. However, the current outcome of second transplantation
      for graft failure is far from satisfactory. We performed a prospective single-arm study to
      investigate the safety and efficacy of a novel regimen.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>engraftment</measure>
    <time_frame>28 days after second transplantation</time_frame>
    <description>Engraftment of neutrophils was defined as the first of 3 consecutive days when the absolute neutrophil count achieved 500/uL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TRM at 28 day</measure>
    <time_frame>28 days after second transplantation</time_frame>
    <description>treatment-related mortality(TRM) was defined as death from any cause other than relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRM at 100d</measure>
    <time_frame>day 100 after second transplant</time_frame>
    <description>treatment-related mortality(TRM) was defined as death from any cause other than relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 100d</measure>
    <time_frame>day100 after second transplantation</time_frame>
    <description>Overall survival at 100d</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Graft Failure</condition>
  <condition>Stem Cell Transplant Complications</condition>
  <arm_group>
    <arm_group_label>intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>second allogeneic stem cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>second allogeneic stem cell transplantation</intervention_name>
    <description>Change another donor
conditioning regimen: FLU/CY/anti-CD25 moAb</description>
    <arm_group_label>intervention arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  graft failure after first allogeneic stem cell transplantation

          -  no active infection or GVHD or severe organ dysfunction

          -  sign written informed consent

        Exclusion Criteria:

          -  active infection, GVHD, organ failure

          -  expected life &lt; 28 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>YUQIAN SUN</last_name>
    <phone>861088324577</phone>
    <email>sunyuqian83@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YUQIAN SUN</last_name>
      <phone>861088324577</phone>
      <email>sunyuqian83@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 30, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Xiaojun Huang,MD</investigator_full_name>
    <investigator_title>Head of Peking University Institute of Hematology</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

